Aleafia Health Provides Further Update on its Convertible Debt
20 Juin 2022 - 1:30PM
Aleafia Health Inc. (TSX: AH, AH.DB, OTCQX: ALEAF)
(“
Aleafia Health” or the
“
Company”) is providing a corporate update
regarding its outstanding listed unsecured convertible debentures
(TSX: AH.DB), issued on June 27, 2019 and maturing on June 27, 2022
(the “
Debentures”). Debentureholders representing
approximately 76.12% of the aggregate principal amount of
Debentures outstanding have executed consents in favour of the
amendments to the Debentures (the “
Debenture
Amendments”) previously announced by the Company on May
12, 2022. This exceeds the required 66 2/3% for the written
extraordinary resolution to approve the Debenture Amendments. The
meeting scheduled for June 23, 2022 will be cancelled.
The transaction is expected to close the week of
June 27, 2022. Upon completion of the transaction, Debentureholders
who timely responded to the consent solicitation by the applicable
deadlines described in the solicitation materials will receive a
consent fee (the “Consent Fee”) calculated as the
amount of accrued interest on the existing Convertible Debentures
between July 1, 2021 and the effective date of the Debenture
Amendments, payable in additional 2028 Debentures at par. For
illustration, if the effective date of the Debenture Amendments
occurs on June 30, 2022, the Consent Fee payable in additional 2028
Debentures at par would be $84.65 per $1,000 principal amount of
Debentures1, or 8.5%, subject to 25% withholding for non-residents
of Canada.
For Investor & Media Relations:
1-833-879-2533
IR@AleafiaHealth.com
LEARN MORE: www.AleafiaHealth.com
About Aleafia Health:
Aleafia Health, a vertically integrated and
federally licensed Canadian cannabis company, owns three licensed
cannabis production facilities, including the first large-scale,
legal outdoor cultivation facility in Canadian history, and
operates a strategically located distribution centre, all in the
province of Ontario. The Company produces a diverse portfolio of
cannabis derivative products including oils, capsules, edibles,
sublingual strips, and vapes, for sale in Canada in the adult-use
and medical markets and is pursuing opportunities in select
international jurisdictions. The Company owns and operates a
virtual network of medical cannabis clinics staffed by physicians
and nurse practitioners.
Forward Looking Information
This news release contains forward-looking
information within the meaning of applicable Canadian and United
States securities laws. Often, but not always, forward-looking
information can be identified by the use of words such as “plans”,
“expects”, “estimates”, “intends”, “anticipates”, or “believes” or
variations of such words and phrases or state that certain actions,
events or results “may”, “could”, “would”, “might” or “will” be
taken, occur or be achieved. Forward-looking information involves
known and unknown risks, uncertainties and other factors which may
cause the actual results, performance or achievements of the
Company or its subsidiaries to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking information contained in this news release.
Risks, uncertainties and other factors involved with
forward-looking information could cause actual events, results,
performance, prospects and opportunities to differ materially from
those expressed or implied by such forward-looking information,
including risks contained in the Company’s annual information form
filed with Canadian securities regulators available on the
Company’s SEDAR profile at www.sedar.com. Although the Company
believes that the assumptions and factors used in preparing the
forward-looking information in this news release are reasonable,
undue reliance should not be placed on such information and no
assurance can be given that such events will occur in the disclosed
time frames or at all. The forward-looking information included in
this news release are made as of the date of this news release and
the Company does not undertake any obligation to publicly update
such forward-looking information to reflect new information,
subsequent events or otherwise unless required by applicable
securities legislation.
1 The Company’s May 12, 2022 reflected an incorrect amount of
the Consent Fee in $s per debenture.
Aleafia Health (TSX:AH)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Aleafia Health (TSX:AH)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024